Introduction to TTLL9 (G164395)

Target Name: TTLL9

NCBI ID: G164395

TTLL9

Introduction to TTLL9

In recent years, there has been substantial progress in identifying new drug targets and biomarkers for various diseases. One such promising target is TTLL9 (Tubby-like protein 9), a protein involved in various signaling pathways. This article aims to explore the significance of TTLL9 as a potential drug target and biomarker, highlighting its role in different diseases and the therapeutic implications associated with this protein.

The Role of TTLL9 in Signaling Pathways:

TTLL9 belongs to the tubby-like family of proteins and plays a crucial role in cellular signaling pathways. It acts as a substrate-specific modifying enzyme involved in the post-translational modification of proteins, especially through the addition of glutamate residues. This modification serves as a regulatory step in multiple signaling cascades, including Wnt, Hedgehog, and Notch pathways.

TTLL9 as a Drug Target:

The specific role of TTLL9 in signaling pathways has sparked interest in its potential as a drug target. By modulating the activity of TTLL9, it is possible to manipulate the functioning of downstream signaling pathways involved in cellular processes. This opens up avenues for targeted therapeutic interventions that could have a significant impact on diseases associated with dysregulated signaling, such as cancer, neurological disorders, and metabolic diseases.

TTLL9 in Cancer:

In cancer, the dysregulation of signaling pathways plays a pivotal role in tumor initiation and progression. Recent studies have highlighted the potential significance of TTLL9 as a therapeutic target in various types of cancer. For instance, TTLL9 has been found to be upregulated in breast cancer cells, and its inhibition can lead to decreased cell proliferation and increased sensitivity to chemotherapeutic agents. Targeting TTLL9 may prove to be a novel strategy for combating cancer and overcoming drug resistance.

TTLL9 in Neurological Disorders:

Neurological disorders, such as Alzheimer's disease and Parkinson's disease, are characterized by dysfunctions in various signaling pathways. Several studies have identified TTLL9 as a potential player in these disorders. In Alzheimer's disease, TTLL9 interacts with tau protein, a key player in neurofibrillary tangle formation. By targeting TTLL9, it is possible to disrupt this interaction and potentially slow down the progression of the disease. Similarly, TTLL9 has been found to modulate the clearance of 伪-synuclein, a protein implicated in Parkinson's disease. Inhibiting TTLL9 activity could enhance the removal of 伪-synuclein aggregates, providing a potential therapeutic avenue for Parkinson's disease treatment.

TTLL9 in Metabolic Diseases:

Metabolic diseases, such as diabetes and obesity, are also influenced by intricate signaling pathways. TTLL9 has been shown to be involved in the regulation of glucose metabolism. Inhibition of TTLL9 has been found to improve glucose tolerance and reduce insulin resistance in preclinical models. This indicates that targeting TTLL9 could be a promising approach for managing metabolic diseases and improving overall metabolic health.

TTLL9 as a Biomarker:

Apart from being a potential drug target, TTLL9 also holds promise as a biomarker for various diseases. Biomarkers are essential in disease diagnosis, prognosis, and monitoring treatment response. TTLL9 expression has been investigated in different cancers, with elevated levels associated with poor prognosis and resistance to therapy. In neurodegenerative disorders, TTLL9 levels have been correlated with disease severity. Additionally, alterations in TTLL9 expression have been reported in metabolic diseases, making it a potential biomarker for monitoring disease progression and therapeutic efficacy.

Conclusion:

TTLL9, a versatile protein involved in multiple signaling pathways, emerges as a promising drug target and biomarker for various diseases. Through its modulation, it is possible to influence signaling cascades and target disease-specific dysregulations. Furthermore, TTLL9 expression levels hold potential as diagnostic and prognostic biomarkers, aiding in personalized medicine approaches. Continued research on TTLL9 will undoubtedly shed light on its full therapeutic potential, providing novel opportunities for combating diverse diseases and improving patient outcomes.

Protein Name: Tubulin Tyrosine Ligase Like 9

Functions: Probable tubulin polyglutamylase that generates side chains of glutamate on the gamma-carboxyl group of specific glutamate residues within the C-terminal tail of target proteins. Similar to TTLL1, may acquire enzymatic activity only in complex with other proteins as it is most likely lacking domains important for autonomous activity. Mediates tubulin polyglutamylation which induces establishment of microtubule heterogeneity in sperm flagella, thereby playing a role in normal motile flagella axoneme structure and sperm flagella beating pattern

The "TTLL9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TTLL9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets